Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2015
April 2015, Vol 6, No 3
April 2015, Vol 6, No 3
Immune Checkpoint Blockade Shows Durable Responses in Lung and Kidney Cancers, Metastatic Melanoma
By
Wayne Kuznar
NCCN Conference Highlights
April 2015, Vol 6, No 3
Hollywood, FL—The National Comprehensive Cancer Network (NCCN) now recommends nivolumab (Opdivo) as subsequent therapy for metastatic squamous non–small-cell lung cancer (NSCLC) after its recent FDA approval.
Read Article
NCCN Issues New Smoking-Cessation Guidelines for Patients with Cancer
By
Wayne Kuznar
NCCN Conference Highlights
April 2015, Vol 6, No 3
Hollywood, FL—A new clinical guideline for smoking cessation in patients with cancer encourages the use of evidence-based pharmacotherapy, behavioral therapy, and close follow-up with retreatment if needed, said Peter G. Shields, MD, Deputy Director, Comprehensive Cancer Center, James Cancer Hospital, Columbus, OH, at the 2015 National Comprehensive Cancer Network (NCCN) conference.
Read Article
Treatment for CLL Will Incorporate More Targeted Therapies in the Near Future
By
Wayne Kuznar
NCCN Conference Highlights
April 2015, Vol 6, No 3
Hollywood, FL—Watch and wait remains the standard of care for patients with asymptomatic early-stage chronic lymphocytic leukemia (CLL), even for high-risk patients, but once therapy is indicated, targeted agents may supplant chemotherapy in the first-line treatment setting, said William G. Wierda, MD, PhD, Center Medical Director, Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX, at the 2015 National Comprehensive Cancer Network (NCCN) annual conference.
Read Article
Choice of Hospital for Readmissions Influences Mortality Risk in Men with Urologic Cancer
By
Chase Doyle
Economics & Value
,
Economics of Cancer Care
April 2015, Vol 6, No 3
Orlando, FL—Patients with urologic cancer who are readmitted after a surgery to a second hospital and not to their original hospital are more likely to have complications than patients readmitted to their original surgical hospital, according to findings presented at the 2015 Genitourinary Cancers Symposium.
Read Article
Millions in Savings by Using Prolaris Test in All Men with Localized Prostate Cancer
By
Alice Goodman
Economics & Value
,
Economics of Cancer Care
April 2015, Vol 6, No 3
Orlando, FL—Significant cost-savings in treating patients with prostate cancer could be achieved in the US healthcare system with the use of the cell-cycle progression (CCP) gene-expression assay called Prolaris (from Myriad Genetics Laboratories), according to a poster from E. David Crawford, MD, Professor of Surgery and Radiation Oncology, University of Colorado, Aurora, and colleagues, presented at the 2015 Genitourinary Cancers Symposium.
Read Article
Insurance Status Impacts Ability to Travel for Care
By
Chase Doyle
Economics & Value
,
Economics of Cancer Care
April 2015, Vol 6, No 3
Orlando, FL—Patients undergoing complex oncologic procedures, such as radical cystectomy, radical prostatectomy, or percutaneous nephrolithotomy, are more likely to travel outside of their regions if they have private insurance, potentially reflecting better access to care based on income, according to findings presented at the 2015 Genitourinary Cancers Symposium.
Read Article
Sunitinib Associated with Higher Costs Compared with Pazopanib in Patients with Renal-Cell Carcinoma
By
Chase Doyle
Economics & Value
,
Economics of Cancer Care
April 2015, Vol 6, No 3
Hollywood, FL—Sunitinib and pazopanib have long battled for supremacy in treating advanced renal-cell carcinoma (RCC). According to findings presented at the 2015 National Comprehensive Cancer Network (NCCN) conference, the newer drug, pazopanib, may have some advantage in terms of total cost of care, but survival outcomes were exactly the same.
Read Article
Value Propositions - April 2015
Value Propositions
,
Value Peer-spectives
April 2015, Vol 6, No 3
Read Article
FDA News - April 2015
FDA Approvals, News & Updates
April 2015, Vol 6, No 3
Read Article
Immunotherapy Vaccine Prolongs Recurrence-Free Survival in Advanced Ovarian Cancer
By
Alice Goodman
Gynecologic Oncology Highlights
,
Immunotherapy
April 2015, Vol 6, No 3
Chicago, IL—Immunotherapy holds promise for the maintenance treatment of late-stage ovarian cancer, according to results of a phase 2 clinical trial. The vaccine, made from the patient’s own tumor cells, was able to prolong recurrence-free survival compared with standard of care.
Read Article
Page 2 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma